Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation Abstract  similar documents
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev
"... . Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has ..."
 
Vol 12, No 1 (2019) Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan Abstract  similar documents
T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova
"... optimization in the Republic of Tatarstan. Materials and methods. A budget impact model was created to compare ..."
 
Vol 13, No 4 (2020) Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy Abstract  similar documents
I. N. Dyakov, S. R. Varfolomeеva
"... -effectiveness analysis) with a sensitivity analysis; and a "budget impact" analysis with a sensitivity analysis ..."
 
Vol 17, No 1 (2024) Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... ,165.00 rubles (–0.4%). The budget impact analysis showed that an increase in the proportion of patients ..."
 
Vol 16, No 3 (2023) Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer Abstract  similar documents
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
"... parameters, budget impact analysis were carried out. Results. The total medical costs for CP/EP + ATZ course ..."
 
Vol 15, No 2 (2022) Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
 
Vol 17, No 4 (2024) Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment Abstract  similar documents
S. К. Zyryanov, I. N. Dyakov
"... and budget impact analysis, with consideration to the efficacy of the compared therapeutic regimens. Data ..."
 
Vol 15, No 1 (2022) Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies Abstract  similar documents
K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina
"... of the budget impact analysis included the costs required for the ovarian stimulation of patients distributed ..."
 
Vol 16, No 2 (2023) Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination Abstract  similar documents
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova
"... (treated separately), ART program cycle, relief of complications. As part of the budget impact analysis ..."
 
Vol 13, No 2 (2020) Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation Abstract  similar documents
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova
"... and budget impact analyses were performed. Results. The drug costs for T+O were the lowest among all ..."
 
Vol 16, No 3 (2023) Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy Abstract  similar documents
S. K. Zyryanov, I. N. Dyakov
"... and third lines of NSCLC therapy. The budget impact analysis demonstrated that if all patients in the target ..."
 
1 - 12 of 12 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)